Thierry Hercend

12.6k citations

117 papers · 10.6k indexed · 3 hit papers · h-index 49

Impact in

Virology top 0.2%
- HIV Research and Treatment
Immunology top 0.1%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses

Papers in

Immunology 98
- Immune Cell Function and Interaction 72
- T-cell and B-cell Immunology 59
- Immunotherapy and Immune Responses 27
Radiology, Nuclear Medicine and Imaging 36
- Monoclonal and Polyclonal Antibodies Research 36

Co-authors: Frédéric Triebel S Jitsukawa Florence Faure S. Chamaret Jean‐Claude Gluckman J Gruest David Klatzmann Denise Guétard
Journals: European Journal of Immunology (20 papers)The Journal of Experimental Medicine (9 papers)The Journal of Immunology (9 papers)International Journal of Cancer (7 papers)Blood (7 papers)
Partner nations: France United States Germany

In The Last Decade

Thierry Hercend

117 papers receiving 10.1k citations

Hit Papers

align trajectories log scale

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo 2004 · 782 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2004 Nature Medicine
1990 The Journal of Experimental Medicine
1984 Nature

Peers

Countries citing papers authored by Thierry Hercend

Since Specialization

Citations

This map shows the geographic impact of Thierry Hercend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Hercend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Hercend more than expected).

Fields of papers citing papers by Thierry Hercend

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Hercend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Hercend. The network helps show where Thierry Hercend may publish in the future.

Co-authors

The 25 scholars most cited alongside Thierry Hercend, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thierry Hercend Line = papers co-authored together Thierry Hercend links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial Clinical Cancer Research ·Pierre Van Damme, A.O. Akinola, Miriam Judith De la Mata Márquez, Ilse De Coster, Christophe Depuydt, Anne Goubier, Viggo Van Tendeloo, Nathalie Cools, Herman Goossens, Thierry Hercend, Benedikt Timmerman, Marie-Christine Bissery	2016	34
2	CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642 The Journal of Immunology ·Géraldine Descamps, Soraya Wuillème‐Toumi, Valérie Trichet, Corinne Venot, Laurent Debüssche, Thierry Hercend, M. Collette, Nelly Robillard, Régis Bataille, Martine Amiot	2006	32
3	A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation European Journal of Immunology ·Emmanuel Zorn, Thierry Hercend	1999	62
4	A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia Leukemia & lymphoma ·Cassandra Ixena, Norbert Vey, Patrice Viens, Anne-Marie Stoppa, E Archimbaud, Michel Attal, D Baume, Réda Bouabdallah, OULAICH Jamal, Joël Fleury, Mauricette Michallet, Daniel Olive, Josy Reiffers, D Sainty, Antonio Tabilio, Pierre Tiberghien, Maud Brandely, Thierry Hercend, Didier Blaise	1998	45
5	T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor β-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases Research in Immunology ·Jos Even, Apiradee Lim, Isabelle Puisieux, Laurent Ferradini, Molly Pinckston, Antoine Toubert, Thierry Hercend, Frédéric Triebel, Christophe Pannetier, Philippe Kourilsky	1995	104
6	T-Cell Receptor Repertoire in Colorectal Adenocarcinoma Patients with Hepatic Metastases and Its Changes Induced by Preoperative Adjuvant Interleukin-2 Therapy Journal of Immunotherapy ·Elena Savelieva, Françoise Farace, Eric Angevin, Dominique Elias, Bernard Escudier, Pierre Duvillard, Thierry Hercend, Frédéric Triebel	1994	7
7	Lymphocyte‐activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4⁺ T lymphocytes European Journal of Immunology ·Bertrand Huard, Najla Edny Monteiro Spessirits, Thierry Hercend, Frédéric Triebel, Florence Faure	1994	189
8	Alternatively spliced T cell receptor transcripts expressed in human T lymphocytes Molecular Immunology ·Sergio Roman‐Roman, Laurent Ferradini, Orly Azogui, Florence Faure, Thierry Hercend, Frédéric Triebel	1993	6
9	CD3.TCR1, A Human CD3 epitope expressed on viable lymphocytes exclusively Cellular Immunology ·Christine Miossec, Catherine Genevée, Thierry Hercend, S Jitsukawa	1992	3
10	T cell target 1 (TCT.1): a novel target molecule for human non-major histocompatibility complex-restricted T lymphocytes. The Journal of Experimental Medicine ·Fathia Mami‐Chouaib, Christine Miossec, Paola Del Porto, Caroline Flament, Frédéric Triebel, Thierry Hercend	1990	32
11	The T-cell receptor Vδ genes predominantly used by human peripheral γ/δ+ T lymphocytes are not rearranged in CD3− natural killer cells Human Immunology ·Sergio Roman‐Roman, Elena Baixerás, Catherine Genevée, Thierry Hercend, Frédéric Triebel	1989	1
12	Characterization of Functional Surface Structures on Human Natural Killer Cells Advances in immunology ·Jerome Ritz, Reinhold Schmidt, Jean Michon, Thierry Hercend, Stuart F. Schlossman	1988	152
13	Evidence for expression of two distinct T cell receptor beta -chain transcripts in a human diphtheria toxoid-specific T cell clone. The Journal of Immunology ·F Triebel, Richard Breathnach, N Hasanmoradi, Thierry Hercend, Patrice Debré	1988	25
14	CD3/Ti gamma A: a functional gamma -receptor complex expressed on human peripheral lymphocytes. The Journal of Immunology ·Florence Faure, S Jitsukawa, Frédéric Triebel, Thierry Hercend	1988	35
15	Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis European Journal of Immunology ·Stefan Meuer, Ulrich Moebius, Michael Manns, Hans Peter Dienes, G Ramadori, Georg Heß, Thierry Hercend, Karl‐Hermann Meyer zum Büschenfelde	1988	60
16	A unique V-J-C-rearranged gene encodes a gamma protein expressed on the majority of CD3+ T cell receptor-alpha/beta- circulating lymphocytes. The Journal of Experimental Medicine ·F Triebel, Florence Faure, N Hasanmoradi, S Jitsukawa, Marie‐Paule Lefranc, Thierry Hercend	1988	123
17	T cells expressing γδ chain receptors in rheumatoid arthritis Journal of Autoimmunity ·Fionula M. Brennan, Marco Londei, Andrew M. Jackson, Thierry Hercend, Michael B. Brenner, Ravinder N. Maini, Marc Feldmann	1988	84
18	Triggering of the phosphoinositide transduction pathway by a monoclonal antibody specific for the human γ/δ T cell receptor European Journal of Immunology ·Georges Bismuth, Florence Faure, Ioannis Théodorou, Patrice Debré, Thierry Hercend	1988	11
19	A novel human V_δ gene expressed predominantly in the TiγA fraction of γ/δ⁺ peripheral lymphocytes European Journal of Immunology ·Frédéric Triebel, Florence Faure, Fathia Mami‐Chouaib, S Jitsukawa, Annelise Bennaceur‐Griscelli, Catherine Genevée, Sergio Roman‐Roman, Thierry Hercend	1988	98
20	Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. The Journal of Experimental Medicine ·Thierry Hercend, Stefan Meuer, Agnes Brennan, M A Edson, Oreste Acuto, Ellis L. Reinherz, S F Schlossman, Jerome Ritz	1983	97

About Thierry Hercend

Thierry Hercend is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging, Oncology, Hematology and Genetics, having authored 117 papers that have together received 10.6k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (72 papers), T-cell and B-cell Immunology (59 papers), Monoclonal and Polyclonal Antibodies Research (36 papers), Immunotherapy and Immune Responses (27 papers), CAR-T cell therapy research (23 papers), Cancer Immunotherapy and Biomarkers (15 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Glycosylation and Glycoproteins Research (5 papers). The work is most often cited by research in Virology (1.7k citations), Immunology (7.0k citations), Oncology (3.0k citations), Hematology (955 citations) and Radiology, Nuclear Medicine and Imaging (1.6k citations). Thierry Hercend has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Frédéric Triebel, S Jitsukawa, Florence Faure, S. Chamaret, Jean‐Claude Gluckman, J Gruest, David Klatzmann, Denise Guétard, Éric Champagne and Luc Montagnier. Their work appears in journals such as European Journal of Immunology, The Journal of Experimental Medicine, The Journal of Immunology, International Journal of Cancer and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact